Barbara A Cannon, president and CEO of Celeris Corporation, explained,
KnowledgePort empowers our customers to continually review their clinical data and evaluate our progress in conducting the clinical research studies. We believe that providing this type of service will result in better relationships with our clients and provide them with a significant advantage in assessing the status of ongoing studies. In effect, our clients will be able to look at data with us during the entire research process, which we believe enhances the value of our quality service.
KnowledgePort was designed to provide continuous access to study conduct and management information using pull technology and provides for virtual private network-type security without installing an operating system or special software. Celeris’ clients and employees will have unprecedented access to study management information as well as access to safety and efficacy data. KnowledgePort also acts as a repository for casebooks scanned into Portable Document Format (PDF) as well as datasets ready for analysis. Through KnowledgePort, tools previously used by Celeris’ employees for the efficient conduct of the clinical research study are now extended to Celeris’ clients.
Dr Donald F Fortin, vice president data management for Celeris, added in a press release, We are very excited to be leading the research services industry with this application technology. KnowledgePort is the integration of a number of best-of-breed hardware and software technologies from vendors such as Oracle, SAS, Verisign, Adobe, Microsoft, Red Hat, and Sun Microsystems. For the first time, our clients will have the ability to access cumulative clinical data – summary reports and datasets. This will enable pharmaceutical, biotech, and device clients to evaluate their clinical data for trend analysis, shorten R and D timelines, and ultimately enhance their chances for product approval on a more timely basis. The use of these tools has already resulted in a reduction of time necessary for database closure as well as a reduction in time required to resolve queries. These efficiencies result in products being approved in a more timely manner.
